Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant

Table 3 NS3 protease domain sequence information

HCV GT	Patient	TW	Outcome	Baseline	End of treatment
1b	Pat.1	24	SVR	Not detected	NA
1b	Pat.2	24	SVR	Not detected	NA
1a	Pat.3	24	SVR	Not detected	NA
1b	Pat.4	24	SVR	Not detected	NA
1b	Pat.5	48	SVR	Not detected	NA
1b	Pat.6	48	SVR	Not detected	NA
1b	Pat.7	48	SVR	Not detected	NA
1b	Pat.8	48	SVR	Not detected	NA
1b	Pat.9	48	SVR	Not detected	NA
1a	Pat.10	48	SVR	Not detected	NA
1b	Pat.11	48	SVR	Not detected	NA
1a	Pat.12	24	Relapse	Not detected	Not done
1a	Pat.13	24	Non response	Not detected	R155K
1a	Pat.14	24	VB	Not detected	V36M, R155K
1b	Pat.15	24	VB	Not detected	-
1a	Pat.16	24	Relapse	V36L	V36L, R155K
1b	Pat.17	16	VB	V36LV	V36L, T54ST
1a	Pat.18	4	Relapse	Not done	R155K
1b	Pat.19	8	VB	Not detected	A156F

Resistance mutations before and after treatment in association with outcome and genotype. HCV: Hepatitis C virus; GT: Genotype; TW: Treatment week; VB: Viral breakthrough; SVR: Sustained viral response (undetectable HCV RNA 24 wk after end of antiviral therapy); NA: Not applied.